Resumo

SUN, Qing et al. NLRP3 inflammasome mechanism and therapeutic targets in diabetic cardiomyopathy. Gac. Méd. Méx [online]. 2023, vol.159, n.3, pp.261-267.  Epub 12-Jun-2023. ISSN 2696-1288.  https://doi.org/10.24875/gmm.m23000749.

Diabetic cardiomyopathy (DCM) is a serious complication of diabetes caused by oxidative stress, inflammation, insulin resistance, myocardial fibrosis, and lipotoxicity; its nature is insidious, complex and difficult to treat. NLRP3 inflammasome triggers the maturation and release of pro-inflammatory cytokines, participates in pathophysiological processes such as insulin resistance and myocardial fibrosis, in addition to being closely related to the development and progression of diabetic cardiomyopathy. The development of inhibitors targeting specific aspects of inflammation suggests that NLRP3 inflammasome can be used to treat diabetic cardiomyopathy. This paper aims to summarize NLRP3 inflammasome mechanism and therapeutic targets in diabetic cardiomyopathy, and to provide new suggestions for the treatment of this disease.

Palavras-chave : Diabetic cardiomyopathy; Pro-inflammatory cytokines; NLRP3 inflammasome.